Recombinant Human CCL3 protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg3309
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | CHO-derived Human CCL3 protein Ser24-Ala92 (Accession# P10147) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 6348 |
| Accession | P10147 |
| PredictedSize | 33.7 kDa |
| SDS-PAGE | 35-39 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in 30mM Tris,500mM arginine, pH 8.0. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
CCL3, also known as macrophage inflammatory protein-1 alpha (MIP-1α), belongs to the CC chemokine family and is a small-molecule cytokine secreted by activated immune cells such as T cells and macrophages. Its primary function is to bind to and activate the chemokine receptors CCR1 and CCR5 on cell surfaces, thereby recruiting and activating various immune cells including monocytes, macrophages, T cells, and dendritic cells. This plays a critical role in infection defense, inflammatory responses, and tumor immune surveillance. Research indicates that CCL3 is aberrantly expressed in conditions such as rheumatoid arthritis, HIV infection, and the microenvironment of various tumors, making it an important therapeutic target for inflammatory diseases and tumor immunotherapy. Receptor antagonists targeting its pathway, such as anti-CCR5 drugs, have already been applied in clinical practice.
References:
1. Soares, Denis Melo et al. Brain research vol. 1269 (2009): 54-60. 2. Barcelos, Lucíola S et al. Microvascular research vol. 78,2 (2009): 148-54. 3. Yang, Ying-Li et al. Rheumatology and therapy vol. 10,4 (2023): 793-808. 4. Ntanasis-Stathopoulos, Ioannis et al. Advances in experimental medicine and biology vol. 1231 (2020): 13-21.
